English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 925736 Online Users : 666
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
Institute of Molecular and Genomic Medicine
Institute of Biotechnology and Pharmaceutical Research
Institute of Biomedical Engineering and Nanomedicine
Immunology Research Center
Center for Neuropsychiatric Research
Institute of Cellular and Systems Medicine
National Institute of Infectious Diseases and Vaccinology
Institute of Population Health Sciences
National Institute of Cancer Research
National Institute of Environmental Health Sciences
National Mosquito-Borne Diseases Control Research Center
National Center for Geriatrics and Welfare Research
Forum
Center of Biomedical Resource
NHRI Graduate Student Program
Core Instrument Center
Pathology Core Laboratory
Laboratory Animal Center
Administrative Units
圖書館
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
NHRI
>
Items for Author
Loading...
Category
Loading community tree, please wait....
Year
Loading year class tree, please wait....
Items for Author "Hubner, RA"
Return to Browse by Author
Showing 9 items.
Collection
Date
Title
Relation
Bitstream
[陳立宗] 期刊論文
2016-02
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
-
[陳立宗] 會議論文/會議摘要
2016-02
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
-
[陳立宗] 會議論文/會議摘要
2016-10
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
-
[陳立宗] 期刊論文
2017-05
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis
-
[陳立宗] 會議論文/會議摘要
2017-09
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon
-
[陳立宗] 期刊論文
2018-06
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
-
[陳立宗] 期刊論文
2018-11-07
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
-
[陳立宗] 期刊論文
2019-01
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
-
[陳立宗] 期刊論文
2019-02
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
-
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback